Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.

Immediate Relief Available

PRINCETON, N.J. - April 7, 2020 - Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic.

The expanded program offers access to any branded Bristol Myers Squibb medicine for free, including some of its most widely prescribed products, as well as those prescribed via telehealth services. The program features:

- Immediate access for patients who have lost their employment and health insurance;
- A simple, single point of entry;
- Streamlined enrollment process; and
- Vouchers to assist with continuity of care for several self-administered BMS medicines, for eligible patients

All Bristol Myers Squibb patient support programs, as well as, additional eligibility requirements, can be reached by calling (800) 721-8909 or by visiting BMS.com.

“The COVID-19 pandemic has created unprecedented financial challenges for patients and families, adding considerable new stress to the millions of Americans who have lost their jobs and health insurance,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol Myers Squibb. “As more patients face difficult decisions in their daily lives, it is important to continue their treatments.”

Bristol Myers Squibb’s Response to COVID-19

Bristol Myers Squibb recognizes this is a challenging time for everyone. The company will continue to take all necessary actions to promote public health and carry out its mission of providing life-saving medicines to the patients who depend on us. Please visit BMS.com to learn more about our actions to date.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Bristol Myers Squibb Contacts

Media:
609-252-3345 media@bms.com
Bristol Myers Squibb Branded Medicines

- ABRAXANE® (protein-bound)
- paclitaxel (albumin-bound)
- ELIQUIS® (apixaban)
- EMPLICITI® (elotuzumab)
- IDHIFA® (enasidenib)
- INREBIC® (fedratinib)
- ISTODAX® (romidepsin)
- NULOJIX® (belatacept)
- OPDIVO® (nivolumab)
- ORENCIA® (abatacept) SC
- ORENCIA® (abatacept) IV
- POMALYST® (pomalidomide)
- REBLOZYL® (luspatercept-aamt)
- REVLIMID® (lenalidomide)
- SPRYCEL® (dasatinib)
- THALOMID® (thalidomide)
- VIDAZA® (azacitidine)
- YERVOY® (ipilimumab)